Expert Illustrations & Commentaries: Translating the Science of Bispecific Antibodies in Solid Tumors – From Mechanisms to Emerging Data

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts John V. Heymach, MD, PhD, and Anne S. Tsao, MD, MBA, FASCO, FACHE, discuss PD-1/CTLA-4, EGFR/PD-1, and DLL3 targeting bispecific antibodies, with a focus on thoracic malignancies.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Describe the structure and mechanisms of emerging PD-1/CTLA-4 bispecific antibodies being evaluated for the treatment of solid tumors
• Describe the mechanistic differences between bispecifics utilizing dual checkpoint blockade and bispecific T-cell engagers, along with potential implications for efficacy and safety
• Integrate the latest data for bispecific therapies into personalized treatment plans for patients with solid tumors

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

Faculty:

John V. Heymach, MD, PhD

Ruth Leggett Jones Distinguished Chair
Chair of Thoracic/Head and Neck Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Advisor/Consultant/Speaker/Honoraria Recipient: 23andMe, AstraZeneca, Bayer, BioNTech AG, BI, BMS, Eli Lilly & Co, Limited, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Mirati Therapeutics, ModeX, Ottimo Pharma, Pfizer, Regeneron Pharmaceuticals, Remunity Therapeutics, Synthekine, Takeda Pharmaceuticals; Grant/Research Funding: AstraZeneca, BMS, BI, Dizal, Taiho, Takeda

Anne S. Tsao, MD, MBA, FASCO, FACHE

Vice President, Academic Affairs
Chief Academic Office
Professor, Thoracic/Head and Neck Medical Oncology
Director, Mesothelioma Program
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Advisor/Consultant/Speaker/Honoraria Recipient:Merck, Astrazeneca, Novartis, Seattle Genetics, Pfizer, Bristol-Meyers Squibb, Eli Lilly; Royalty or Patent Benefits: UptoDate

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on the mechanisms of action of bispecific antibodies and pros and cons of using these agents, go to https://www.gotoper.com/eic26bispecifics-activity.

Release Date

February 26, 2026

Expiration Date

February 26, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.